Alimera Sciences (NASDAQ:ALIM) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th. Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a research note on Tuesday, June 25th.

Alimera Sciences Stock Performance

ALIM opened at $5.54 on Friday. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. Alimera Sciences has a 52 week low of $2.61 and a 52 week high of $5.65. The business’s 50 day moving average is $5.55 and its two-hundred day moving average is $4.47. The firm has a market cap of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. On average, research analysts predict that Alimera Sciences will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Alimera Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deltec Asset Management LLC acquired a new stake in shares of Alimera Sciences in the 2nd quarter valued at approximately $690,000. Vanguard Group Inc. raised its position in Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after acquiring an additional 396,506 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Alimera Sciences in the first quarter valued at $915,000. Glazer Capital LLC purchased a new stake in shares of Alimera Sciences during the 2nd quarter worth $3,067,000. Finally, Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences during the 1st quarter worth $83,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).